CMV and immune changes in kidney transplant patients
Treatments studied
Part of Infections clinical trials.
This study looks at how CMV (a common virus) affects the immune system in people who get a kidney transplant or have CMV after transplant. It may help doctors understand and manage CMV better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You are scheduled to receive a kidney transplant from a living donor.
- Or you have already received a kidney transplant and now have CMV virus in your blood.
- You are not under guardianship or legal protection.
- You do not have an active infection (other than CMV) before transplant.
- You are not receiving special desensitization therapy for ABO or HLA incompatibility.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses a blood test (QuantiFERON-CMV) to help decide whether people with a silent (no symptoms) CMV infection after a solid organ transplant need treatment. If you have a low-to-moderate level of CMV in your blood without fever or organ issues, this trial may help your doctor choose the safest approach.
This trial tests a combination of two antiviral drugs (letermovir and valganciclovir) to treat CMV infections in kidney transplant recipients. It aims to find a safer, more effective treatment option for people with active CMV after transplant.
This study compares two strategies to prevent a viral infection called CMV after kidney transplant. It tests whether an “immune-guided” approach (using your immune test results) can prevent CMV as well as or better than giving preventive antiviral medicine to everyone.
This trial tests whether using a blood test that measures your immune system's ability to fight CMV (a common virus) can guide when to stop anti-CMV drugs after a lung transplant, aiming to prevent the virus from causing disease.
This trial tests a special machine that washes a donated kidney with a drug to remove a common virus called CMV before transplant. It may help prevent the virus from infecting the person who receives the kidney.
This trial tests two ways to prevent CMV in kidney transplant patients who are at high risk. It compares giving antiviral medicine preemptively (based on regular blood tests) versus giving it as prophylaxis (starting right after transplant). The goal is to see which approach prevents CMV infection better.
Hear when a new Kidney Transplantation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.